Biogen Inc. (BIIB) reported $2.43 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 6.1%. EPS of $3.02 for the same period compares to $3.67 a year ago.
The reported revenue represents a surprise of +8.91% over the Zacks Consensus Estimate of $2.23 billion. With the consensus EPS estimate being $3.26, the EPS surprise was -7.36%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Biogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Product- Rare Disease- SKYCLARYS - Rest of World: $54.80 million compared to the $33.02 million average estimate based on 22 analysts.
- Revenue- Product- Rare Disease- SKYCLARYS - United States: $69.10 million versus $74.12 million estimated by 22 analysts on average.
- Revenue- Product- Rare Disease- SPINRAZA- United States: $154.40 million versus $160.72 million estimated by 22 analysts on average. Compared to the year-ago quarter, this number represents a +4% change.
- Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- United States: $39.80 million versus $31.40 million estimated by 22 analysts on average. Compared to the year-ago quarter, this number represents a -8.9% change.
- Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Total: $381.50 million compared to the $364.47 million average estimate based on 26 analysts. The reported number represents a change of -11.6% year over year.
- Revenue- Product- Rare Disease- SPINRAZA- Total: $423.90 million versus the 26-analyst average estimate of $365 million. The reported number represents a year-over-year change of +24.2%.
- Revenue- Anti-CD20 therapeutic programs: $378 million versus $411.57 million estimated by 25 analysts on average. Compared to the year-ago quarter, this number represents a -4.1% change.
- Revenue- Product- Rare Disease- SKYCLARYS- Total: $123.90 million versus the 25-analyst average estimate of $107.53 million.
- Revenue- Product, net: $1.73 billion versus $1.66 billion estimated by 25 analysts on average. Compared to the year-ago quarter, this number represents a +0.9% change.
- Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- Total: $206.10 million versus the 24-analyst average estimate of $201.12 million. The reported number represents a year-over-year change of -19%.
- Revenue- Product- Multiple Sclerosis (MS)- Total: $953 million versus $925.29 million estimated by 24 analysts on average. Compared to the year-ago quarter, this number represents a -11.4% change.
- Revenue- Product- Multiple Sclerosis (MS)- Fumarate- VUMERITY- Total: $138.80 million versus the 24-analyst average estimate of $141.23 million. The reported number represents a year-over-year change of +8.9%.
View all Key Company Metrics for Biogen here>>>
Shares of Biogen have returned -7.8% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Biogen Inc. (BIIB): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
